Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Common Equity (2017 - 2025)

Historic Common Equity for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $265.5 million.

  • Autolus Therapeutics' Common Equity fell 4434.56% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year decrease of 4434.56%. This contributed to the annual value of $427.3 million for FY2024, which is 28334.05% up from last year.
  • Per Autolus Therapeutics' latest filing, its Common Equity stood at $265.5 million for Q3 2025, which was down 4434.56% from $346.5 million recorded in Q2 2025.
  • Autolus Therapeutics' Common Equity's 5-year high stood at $582.0 million during Q1 2024, with a 5-year trough of $111.5 million in Q4 2023.
  • Its 5-year average for Common Equity is $309.1 million, with a median of $283.7 million in 2021.
  • As far as peak fluctuations go, Autolus Therapeutics' Common Equity plummeted by 6267.7% in 2023, and later skyrocketed by 28334.05% in 2024.
  • Over the past 5 years, Autolus Therapeutics' Common Equity (Quarter) stood at $313.3 million in 2021, then fell by 4.67% to $298.7 million in 2022, then plummeted by 62.68% to $111.5 million in 2023, then surged by 283.34% to $427.3 million in 2024, then crashed by 37.88% to $265.5 million in 2025.
  • Its Common Equity stands at $265.5 million for Q3 2025, versus $346.5 million for Q2 2025 and $371.1 million for Q1 2025.